[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.107.222. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 24, 1996

Stress Ulcer Prophylaxis in Critically III PatientsResolving Discordant Meta-analyses

Author Affiliations

From the Departments of Medicine (Drs Cook, Reeve, and Guyatt) and Clinical Epidemiology and Biostatistics (Drs Cook, Guyatt, and Heyland and Mss Griffith and Buckingham), McMaster University Faculty of Health Sciences, Hamilton, Ontario; and the Department of Anaesthesiology, Intensive Care Medicine, and Pain Therapy, University Hospital Bergmannsheil, Bochum, Germany (Dr Tryba). Dr Cook is a Career Scientist of the Ontario Ministry of Health.

JAMA. 1996;275(4):308-314. doi:10.1001/jama.1996.03530280060038
Abstract

Purpose.  —To resolve discrepancies in previous systematic overviews and provide estimates of the effect of stress ulcer prophylaxis on gastrointestinal bleeding, pneumonia, and mortality in critically ill patients.

Data Identification.  —Computerized search of published and unpublished research, bibliographies, pharmaceutical and personal files, and conference abstract reports.

Study Selection.  —Independent review of 269 articles identified 63 relevant randomized trials for inclusion.

Data Abstraction.  —We made independent, duplicate assessment of the methodologic quality, population, intervention, and outcomes of each trial.

Results.  —The source of discrepancies between prior meta-analyses included incomplete identification of relevant studies, differential inclusion of non—English language and nonrandomized trials, different definitions of bleeding, provision of additional information through direct correspondence with authors, and different statistical methods. The current overview demonstrates that prophylaxis with histamine2-receptor antagonists decreases the incidence of overt gastrointestinal bleeding (odds ratio [OR], 0.58; 95% confidence interval [CI], 0.42 to 0.79) and clinically important bleeding (OR, 0.44; 95% CI, 0.22 to 0.88). There is a trend toward decreased overt bleeding when antacids are compared with no therapy (OR, 0.66; 95% CI, 0.37 to 1.17). Histamine2-receptor antagonists and antacids are associated with a trend toward lower clinically important bleeding rates than sucralfate is. There is a trend toward an increased risk of pneumonia associated with histamine2-receptor antagonists as compared with no prophylaxis (OR, 1.25; 95% CI, 0.78 to 2.00). Sucralfate is associated with a lower incidence of nosocomial pneumonia when compared with antacids (OR, 0.80; 95% CI, 0.56 to 1.15) and histamine2-receptor antagonists (OR, 0.77; 95% CI, 0.60 to 1.01). Sucralfate is also associated with a reduced mortality rate (OR, 0.73; 95% CI, 0.54 to 0.97) relative to antacids and to histamine2-receptor antagonists (OR, 0.83; 95% CI, 0.63 to 1.09).

Conclusions.  —Our results emphasize the need for registries to include all randomized trials and demonstrate the importance of explicit methodology for systematic reviews. There is strong evidence of reduced clinically important gastrointestinal bleeding with histamine2-receptor antagonists. Sucralfate may be as effective in reducing bleeding as gastric pH—altering drugs and is associated with lower rates of pneumonia and mortality. However, the data are insufficient to determine the net effect of sucralfate compared with no prophylaxis.(JAMA. 1996;275:308-314)

×